Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Murray Rosenbaum

Clinical Cardiac Electrophysiology Boca Raton, FL Medical Doctor

NPI 1639113152 CMS profile 346512

1200 N Federal Hwy, Suite 100, Boca Raton, FL 33432

Open in the dashboard

General payments

$34,015

422 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Murray Rosenbaum of Boca Raton, FL is reported in the CMS Open Payments database as having received $34,015 across 422 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,175 46
2024 General $2,962 57
2023 General $4,721 77
2022 General $1,421 69
2021 General $2,241 49
2020 General $2,317 52
2019 General $19,176 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Murray Rosenbaum
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Murray Rosenbaum were reported at $1,175. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Murray Rosenbaum Clinical Cardiac Electrophysiology median Middle half National median
2019 $19,176 $2,361 $585–$8,260 $163
2020 $2,317 $993 $247–$4,351 $114
2021 $2,241 $1,185 $326–$4,739 $132
2022 $1,421 $2,073 $554–$6,789 $149
2023 $4,721 $2,568 $759–$8,159 $160
2024 $2,962 $2,557 $703–$7,403 $164
2025 $1,175 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $20,858 52 payments
  2. Medtronic, Inc. $3,464 86 payments
  3. Boston Scientific Corporation $3,148 11 payments
  4. Abbott Laboratories $1,467 42 payments
  5. Medtronic Vascular, Inc. $1,105 33 payments
  6. Biosense Webster, Inc. $687 39 payments
  7. Pfizer Inc. $659 35 payments
  8. Sanofi-Aventis U.S. LLC $484 23 payments
  9. Cardiva Medical, Inc. $414 18 payments
  10. E.R. Squibb & Sons, L.L.C. $400 22 payments
  11. Other $1,329 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,100 15 payments
  2. Food and Beverage $9,939 399 payments
  3. Travel and Lodging $1,676 7 payments
  4. Consulting Fee $300 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $20,858 52 payments
  2. PULSESELECT $1,345 8 payments
  3. ARCTIC FRONT ADVANCE $754 21 payments
  4. ELIQUIS $606 32 payments
  5. Arctic Front $498 8 payments
  6. Carto 3 $477 27 payments
  7. Micra $453 10 payments
  8. Confirm Rx $338 4 payments
  9. Cardiva VASCADE MVP VVCS 6-12F $316 14 payments
  10. MULTAQ $310 13 payments
  11. Other $5,238 237 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,888

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$819,602

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

44.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 405 $394,777
Xarelto Rivaroxaban Brand 177 $189,714
Multaq Dronedarone Hcl Brand 121 $160,215
Disopyramide Phosphate Generic 92 $17,963
Flecainide Acetate Generic 378 $14,422
Dofetilide Generic 56 $14,099
Corlanor Ivabradine Hcl Brand 22 $11,323
Mexiletine Hcl Generic 23 $3,036
Metoprolol Succinate Generic 212 $2,888
Propafenone Hcl Er Propafenone Hcl Brand 20 $2,839

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$913,907

Medicare's payments for the services billed

Medicare patients

2,890

Average age 81

Services billed

10,319

1,305 women, 1,585 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 65%
Arthritis 59%
Heart failure 43%
Chronic kidney disease 39%
Diabetes 36%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $128
$128 121 —
ELIQUIS
  • PFIZER INC. $89
  • E.R. Squibb & Sons, L.L.C. $31
$120 405 —
XARELTO
  • Janssen Pharmaceuticals, Inc $82
$82 177 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $68
$68 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $40
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

422 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record